SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chambers TJ, Hall TJ 1991 Cellular and molecular mechanism in the regulation and function of osteoclasts Vitam Horm 46:4186.
  • 2
    Roodman GD 1996 Advances in bone biology: The osteoclast Endocr Rev 17:308332.
  • 3
    Suda T, Nakamura I, Jimi E, Takahashi N 1997 Regulation of osteoclast function J Bone Miner Res 12:869879.
  • 4
    Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, Teitelbaum SL 1997 Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 Nature 386:8184.
  • 5
    Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S 1990 The murine mutation osteoporosis is in the coding region of the macrophage colony stimulating factor gene Nature 345:442444.
  • 6
    Grigoriadis AE, Wang Z-Q, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 Fos: A key regulator of osteoclast-macrophage lineage determination and bone resorption Science 266:443448.
  • 7
    Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, Jenkins NA, Arnheiter H 1993 Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein Cell 74:395404.
  • 8
    Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-κB1 and NF-κB2 Nat Med 3:12851289.
  • 9
    Soriano P, Montogomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice Cell 64:693702.
  • 10
    Gelb BD, Shi G-P, Chapman HA, Desnick RJ 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency Science 273:12361238.
  • 11
    Kanis JA, Melton JL, Christiansen C, Johnston CC, Khaltaev N 1994 The diagnosis of osteoporosis J Bone Miner Res 9:11371141.
  • 12
    Pacifici R 1996 Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis J Bone Miner Res 11:10431051.
  • 13
    Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis N Engl J Med 332:305311.
  • 14
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β Nat Med 2:11321136.
  • 15
    Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis Biochem Biophys Res Commun 234:137142.
  • 16
    Yasuda Y, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139:13291337.
  • 17
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen H-Q, Wooden S, Bennet L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Lee R, Amgen EST Program, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 89:309319.
  • 18
    Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H, Morinaga T, Tsuda E, Higashio K 1998 Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor Biochem Biophys Res Commun 245:382387.
  • 19
    Köhler G, Milstein C 1975 Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256:495497.
  • 20
    Washida N, Kitawaki J, Higashiyama T, Matsui S, Osawa Y 1996 Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450 Steroids 61:126132.
  • 21
    Friguet B, Chaffotte AF, Ohaniance LD, Goldberg ME 1985 Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay J Immunol Meth 77:305319.
  • 22
    Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y 1998 Diagnostic criteria of primary osteoporosis J Bone Miner Metab 16:139150.
  • 23
    Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y 1995 Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency J Clin Endocrinol Metab 80:19221928.
  • 24
    Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K 1998 Characterization of structural domains of human osteoclastogenesis inhibitory factor J Biol Chem 273:51175123.
  • 25
    Cascino I, Fiucci G, Papoff G, Ruberti G 1995 Three functional soluble forms of the human apoptosis-induced Fas molecule are produced by alternative splicing J Immunol 154:27062713.
  • 26
    Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H, Wallach D 1990 Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor EMBO J 9:32693278.
  • 27
    Ashkenazi A, Mardtars SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Paladino MA, Smith DH 1991 Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin Proc Natl Acad Sci USA 88:1053510539.
  • 28
    Peppel K, Crawfold D, Beutler B 1991 A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity J Exp Med 174:14831489.
  • 29
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95:35973602.
  • 30
    Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93:165176.
  • 31
    Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y 1998 Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells J Biol Chem 273:2709127096.
  • 32
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12:12601268.
  • 33
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H 1998 Severe osteoporosis in mice lacking OCIF/OPG (osteoclastogenesis inhibitory factor/osteoprotegerin) Biochem Biophys Res Commun 247:610615.